Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Titel:
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Auteur:
Calmy, Alexandra Tovar Sanchez, Tamara Kouanfack, Charles Mpoudi-Etame, Mireille Leroy, Sandrine Perrineau, Ségolène Lantche Wandji, Martial Tetsa Tata, Darius Omgba Bassega, Pierette Abong Bwenda, Thérèse Varloteaux, Marie Tongo, Marcel Mpoudi-Ngolé, Eitel Montoyo, Alice Mercier, Noémie LeMoing, Vincent Peeters, Martine Reynes, Jacques Delaporte, Eric